At the core of the MAA submission are positive data from the pivotal Phase 2b VISION-DMD study which comprised a (1) 24-week period to demonstrate efficacy and safety of vamorolone […]
Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001 Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs […]
Dr. Paolo Bettica will review recently completed study analysis for the Italfarmaco Phase 3 randomized controlled trial of givinostat in boys with Duchenne muscular dystrophy (DMD). He will answer your […]
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 4-month interim results […]
An interview with the Millers and Ryan Getzlaf discussing the Getzlaf Golf Shootout that originally aired on NBC4
– Initiation of LYNX Phase 2 clinical trial in individuals with DMD expected in Q4 2022 – Boulder, Colo., (September 7, 2022) – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage […]
As an early funder of Dyne Therapeutics, CureDuchenne is pleased to share that Dyne has dosed the first participant in their clinical trial in Duchenne amenable to skipping exon 51.
